Arcellx Updates Tender Offer for Gilead Acquisition, Extends Expiration, and Reports Regulatory Clearances & Lawsuits

summarizeSummary

Arcellx filed an amendment to its Schedule 14D-9, extending the tender offer expiration for the Gilead acquisition to April 24, 2026, confirming HSR Act clearance, and disclosing new stockholder lawsuits.

check_boxKey Events

• Tender Offer Extended

  Gilead Sciences extended its tender offer to acquire Arcellx until April 24, 2026, from the previous April 2, 2026 expiration. The offer terms of $115.00 cash per share plus a $5.00 CVR remain unchanged.

• HSR Act Clearance Achieved

  The waiting period under the HSR Act expired on March 31, 2026, satisfying a key condition for the acquisition.

• New Stockholder Lawsuits Filed

  Two lawsuits were filed in New York Supreme Court on March 16 and March 18, 2026, alleging misleading disclosures in the Schedule 14D-9 and seeking to enjoin the transaction. Sixteen demand letters were also received. Arcellx believes these claims are without merit.

• International Regulatory Updates

  Notifications were submitted to Austrian and Australian competition authorities, while the German Federal Cartel Office (FCO) deemed notification unnecessary and the filing was withdrawn.

auto_awesomeAnalysis

This amendment provides crucial updates on the ongoing acquisition of Arcellx by Gilead Sciences. The extension of the tender offer expiration date to April 24, 2026, confirms the deal is progressing, albeit with a slight procedural delay. The satisfaction of the HSR Act waiting period is a significant positive step, removing a key regulatory hurdle for the transaction's completion. While new stockholder lawsuits have been filed, these are common in M&A transactions and the company believes them to be without merit, suggesting they may not materially impede the deal. Investors should monitor the tender offer's progress and any further legal developments.